Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 20 10:41AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-37.21 Insider Own2.43% Shs Outstand1.23M Perf Week8.41%
Market Cap6.03M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.20M Perf Month13.16%
Income-12.23M PEG- EPS next Q- Inst Own4.06% Short Float2.51% Perf Quarter-3.47%
Sales0.00M P/S- EPS this Y- Inst Trans-62.35% Short Ratio0.55 Perf Half Y-16.74%
Book/sh20.32 P/B0.24 EPS next Y- ROA-13.75% Short Interest0.03M Perf Year-79.08%
Cash/sh22.98 P/C0.21 EPS next 5Y- ROE-16.94% 52W Range3.53 - 47.00 Perf YTD-27.91%
Dividend Est.- P/FCF- EPS past 5Y8.59% ROI-55.44% 52W High-89.57% Beta1.50
Dividend TTM- Quick Ratio4.58 Sales past 5Y0.00% Gross Margin- 52W Low38.91% ATR (14)0.43
Dividend Ex-Date- Current Ratio4.58 EPS Y/Y TTM-145.64% Oper. Margin0.00% RSI (14)54.44 Volatility8.09% 8.64%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price350.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q93.78% Payout- Rel Volume0.47 Prev Close4.75
Sales Surprise- EPS Surprise0.00% Sales Q/Q- Earnings- Avg Volume55.18K Price4.90
SMA205.07% SMA504.28% SMA200-31.11% Trades Volume5,836 Change3.16%
May-07-24 09:00AM
Apr-24-24 09:15AM
Apr-09-24 09:15AM
Apr-03-24 08:00AM
Dec-19-23 09:00AM
09:00AM Loading…
Dec-06-23 09:00AM
Nov-02-23 09:00AM
Sep-26-23 09:00AM
Sep-07-23 09:00AM
Jul-19-23 09:00AM
Jul-13-23 09:00AM
Mar-07-23 09:00AM
Dec-16-22 09:00AM
Nov-18-22 09:00AM
Oct-19-22 09:00AM
11:50AM Loading…
Sep-28-22 11:50AM
Aug-12-22 09:00AM
Jul-26-22 09:15AM
Jul-21-22 09:15AM
Jul-20-22 09:15AM
May-17-22 09:15AM
Apr-19-22 09:15AM
Apr-05-22 09:15AM
Mar-29-22 09:15AM
Mar-22-22 09:15AM
Mar-15-22 09:15AM
Feb-23-22 09:15AM
Feb-07-22 09:38AM
Feb-01-22 09:15AM
Dec-06-21 11:58AM
09:00AM Loading…
Sep-28-21 09:00AM
Sep-10-21 09:00AM
Aug-05-21 10:00AM
Jul-26-21 09:15AM
Jul-21-21 09:00AM
Jul-14-21 09:00AM
Jul-07-21 09:00AM
Jun-24-21 09:00AM
Jun-14-21 09:00AM
Jun-09-21 09:00AM
May-19-21 09:00AM
May-10-21 09:00AM
Apr-26-21 09:00AM
Apr-01-21 09:00AM
Mar-05-21 09:00AM
Feb-25-21 09:12AM
Feb-12-21 09:00AM
Feb-09-21 09:00AM
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer's disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson's Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.